Category: News
What Veteran's Day Means to the MRA Team
6 November 2023 In News, Prevention
In observation of Veteran's Day - November 11 - we asked the MRA team to create short videos explaining what the day means for them and what they want Veterans and other military personnel to know about their risk for melanoma, other skin cancers, and the importance of sun safety.
What Melanoma Patients Need to Know about Hepzato Kit
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 October 2023 In News, Science, Treatment
You may have heard of Hepzato Kit, also known as Liver-Directed Melphalan, the first liver-directed therapy available for patients with metastatic uveal melanoma who have liver metastases that cannot be surgically removed.
MRA Statement on Expanded Approval of Nivolumab to Patients with Stage 2 Disease
13 October 2023 In News, Science, Treatment
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Bristol Myers Squibb’s Opdivo (nivolumab) to include patients with completely resected Stage IIB and IIC melanoma.
A Message from Our CEO on Rare Cancer Day
By Marc Hurlbert, PhD, MRA Chief Executive Officer | 30 September 2023 In Melanoma Stories, News, Science
Acral, mucosal, pediatric, and uveal melanomas – what we collectively call rare melanomas – represent an area of profound unmet medical need. Learn what MRA is doing to accelerate research focused on rare melanomas.
Dr. Hussein Tawbi: Opdualag Clinical Trial Updates
By Tanisha Jackson, PhD - MRA Scientific Program Director | 18 September 2023 In Allies & Partnerships, Events, News, Science, Treatment
In March of 2022, the melanoma community celebrated the FDA approval of nivolumab + relatlimab (brand name Opdualag), a new treatment for patients with metastatic melanoma that combines two different immunotherapies, nivolumab and relatlimab, into one medicine.
MRA Statement on FDA Approval of Hepzato Kit for Patients with Uveal Melanoma with Liver Metastases
16 August 2023 In News, Treatment
The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Joan Levy, PhD and MRA Chief Executive Officer Marc Hurlbert, PhD on the Food & Drug Administration approval of Hepzato Kit for patients with uveal melanoma with liver metastases that cannot be surgically removed.
MRA's Latest Research Report: Reaching for the Stars
25 July 2023 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment
Each year, MRA convenes global thought leaders from across the melanoma research community to exchange ideas, report on scientific successes and challenges, and network and forge new collaborations.
Reflecting on a Decade of Progress and Future Heights in Melanoma
21 July 2023 In Allies & Partnerships, News, Science, Treatment
If you told Dr. Jedd Wolchok at the start of his oncology career what melanoma research would look like today, he likely wouldn’t believe you. Wolchok, now a world-renowned medical oncologist and Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, originally faced an alternate...
Melanoma Research Alliance Announces 2023 Dermatology Fellowship Award Recipients
20 July 2023 In News, Prevention, Science
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, is proud to announce its 2023 Dermatology Fellowship Award recipients. MRA’s Dermatology Fellowship program is building a pipeline of scientists and clinicians who specialize in melanoma, the deadliest form of skin cancer and the fifth most common cancer in the United States.
MRA's RARE Registry for Acral & Mucosal Melanoma Surpasses 100-Patient Milestone
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 10 July 2023 In Melanoma Stories, News, Science
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced that the RARE Registry for acral and mucosal melanoma has officially surpassed 100 patients, making it the largest registry of its kind in the world and marking an important milestone in advancing cutting-edge research for these rare and difficult-to-treat melanoma subtypes.